Halozyme is a pioneering biotechnology company committed to enhancing patient experiences through innovative drug delivery solutions. Their core focus is on developing disruptive technologies that streamline treatment protocols, making therapies more convenient for patients. Central to their mission is the ENHANZE® technology platform, which utilizes the proprietary enzyme rHuPH20 to facilitate the subcutaneous delivery of medications, transforming lengthy intravenous infusions into quick subcutaneous injections.

Halozyme also provides a suite of specialized auto-injectors, drawing from over 30 years of expertise in device development. Their commercial portfolio includes two FDA-approved products: HYLENEX® (hyaluronidase injection) and XYOSTED® (testosterone enanthate), showcasing their commitment to combining advanced delivery technologies with effective therapeutic options.

Driven by a strong set of values, Halozyme emphasizes collaboration, patient focus, integrity, and innovation, striving to positively impact the lives of patients and their families while fostering a strong commitment to corporate responsibility and ethical standards in all their endeavors.